Arcus Biosciences Stock Quote RCUS - Stock Price, News, Charts, Message Board, Trades

Professional-Grade Tools, for Individual Investors.

Premium

Current Price

13.83

Bid

Ask

Volume

635,327

13.76 Day's Range 14.43

12.95 52 Week Range 25.47

Market Cap

1.284B

Previous Close

14.12

Open

14.19

Last Trade

100

13.83

(formt)

Last Trade Time

Financial Volume

$ 8,910,281

VWAP

14.0247

Average Volume (3m)

733,709

Shares Outstanding

90,953,011

Dividend Yield

PE Ratio

-4.10

Earnings Per Share (EPS)

-3.38

Revenue

117M

Net Profit

-307M

Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule... Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB680, and Zimberelimab. Arcus conducts clinical trials for different types of cancers such as Prostate, Lung, Colorectal, Pancreatic, and others. The company operates through the single segment being the business of developing and commercializing immunotherapies. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.arcusbio.com

Headquarters

Camden, Delaware, USA

Founded

1970

Arcus Biosciences Inc is listed in the Pharmaceutical Preparations sector of the New York Stock Exchange with ticker RCUS. The last closing price for Arcus Biosciences was $14.12. Over the last year, Arcus Biosciences shares have traded in a share price range of $ 12.95 to $ 25.47.

Arcus Biosciences currently has 90,953,011 shares outstanding. The market capitalization of Arcus Biosciences is $1.28 billion. Arcus Biosciences has a price to earnings ratio (PE ratio) of -4.10.

Arcus Biosciences Completes Patient Enrollment in Phase 3 Trial Evaluating a Domvanalimab-Containing Regimen in First-Line Metastatic Upper GI Cancers

Domvanalimab is the only anti-TIGIT antibody in Phase 3 for upper gastrointestinal (GI) adenocarcinomas with the potential to be first-to-market for this patient population Arcus Biosciences...

Form 4 - Statement of changes in beneficial ownership of securities

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-1.36	-8.95325872284	15.19	15.47	13.61	549148	14.53637962	CS
4	-1.44	-9.43025540275	15.27	17.18	13.61	1001333	15.87905579	CS
12	-2.73	-16.4855072464	16.56	18.07	13.61	733709	15.89546423	CS
26	-3.9	-21.9966159052	17.73	20.31	13.61	789414	16.70159792	CS
52	-8.07	-36.8493150685	21.9	25.47	12.95	793563	17.52623032	CS
156	-14.45	-51.0961810467	28.28	49.1	12.95	855254	23.81708658	CS
260	5.23	60.8139534884	8.6	49.1	6.3	703217	24.06181161	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
SHPWShapeways Holdings Inc	$ 0.5041 (140.05%)	92.12M
ZAPPZapp Electric Vehicles Group Ltd	$ 9.25 (127.27%)	105.04M
IVPInspire Veterinary Partners Inc	$ 2.94 (97.32%)	54.79M
VRPXVirpax Pharmaceuticals Inc	$ 1.10 (90.31%)	161.22M
MORFMorphic Holding Inc	$ 55.71 (74.97%)	53.24M
HLVXHilleVax Inc	$ 1.63 (-88.41%)	25.63M
CLEUChina Liberal Education Holdings Ltd	$ 0.568999 (-73.90%)	15.69M
SYTSYLA Technologies Company Ltd	$ 2.07 (-31.91%)	534.24k
CJETChijet Motor Company Inc	$ 6.00 (-25.93%)	188.91k
WETHWetouch Technology Inc	$ 2.44 (-22.78%)	518.66k
MAXNMaxeon Solar Technologies Ltd	$ 0.2722 (13.42%)	493.33M
NVDANVIDIA Corporation	$ 128.20 (1.88%)	237.64M
VRPXVirpax Pharmaceuticals Inc	$ 1.10 (90.31%)	161.22M
TSLATesla Inc	$ 252.94 (0.56%)	157.26M
SVMHSRIVARU Holding Ltd	$ 0.1874 (17.94%)	121.4M